Palliative treatment in patients with oesophagus carcinoma;De palliatieve behandeling van patiënten met een oesofaguscarcinoom

Nederlands Tijdschrift voor Geneeskunde

Volumn 149, Issue 50, 2005, Pages 2775-2782

  Siersema, P D ^a   Verschuur, E M L ^a   Homs, M Y V ^a   Van Der Gaast, A ^a   Eijkenboom, W M H ^a   Kuipers, E J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; DYSPHAGIA; ESOPHAGUS CARCINOMA; ESOPHAGUS METASTASIS; EXTERNAL BEAM RADIOTHERAPY; HUMAN; QUALITY OF LIFE; REVIEW; SYMPTOM; TREATMENT PLANNING; VALIDATION STUDY;

BRACHYTHERAPY; CARCINOMA; DEGLUTITION DISORDERS; ESOPHAGEAL NEOPLASMS; ESOPHAGEAL STENOSIS; HUMANS; LIFE EXPECTANCY; PALLIATIVE CARE; QUALITY OF LIFE;

EID: 29144536253     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Visser O. Incidence of cancer in the Netherlands 1998; tenth report of the Netherlands Cancer Registry. Utrecht: Vereniging van Integrale Kankercentra; 2002.
2. Lerut T, Coosemans W, Decker G, Leyn P de, Nafteux P, Raemdonck D van. Cancer of the esophagus and gastro-esophageal junction: potentially curative therapies. Surg Oncol. 2001;10:113-22.
3. Siersema PD, Marcon N, Vakil N. Metal stents for tumors of the distal esophagus and gastric cardia. Endoscopy. 2003;35:79-85.
4. Bartelsman JF, Bruno MJ, Jensema AJ, Haringsma J, Reeders JW, Tytgat GN. Palliation of patients with esophagogastric neoplasms by insertion of a covered expandable modified Gianturco-Z endoprosthesis: experiences in 153 patients. Gastrointest Endosc. 2000;51:134-8.
5. Thompson AM, Rapson T, Gilbert FJ, Park KG. Endoscopic palliative treatment for esophageal and gastric cancer: techniques, complications, and survival in a population-based cohort of 948 patients. Surg Endosc. 2004;18:1257-62.
6. Homs MY, Steyerberg EW, Kuipers EJ, Gaast A van der, Haringsma J, Blankenstein M van, et al. Causes and treatment of recurrent dysphagia after self-expanding metal stent placement for palliation of esophageal carcinoma. Endoscopy. 2004;36:880-6.
7. Nickers P, Kunkler I, Scalliet P. Modern brachytherapy: current state and future prospects. Eur J Cancer. 1997;33:1747-51.
8. Sur RK, Levin CV, Donde B, Sharma V, Miszczyk L, Nag S. Prospective randomized trial of HDR brachytherapy as a sole modality in palliation of advanced esophageal carcinoma - an International Atomic Energy Agency study. Int J Radiat Oncol Biol Phys. 2002;53:127-33.
9. Sharma V, Mahantshetty U, Dinshaw KA, Deshpande R, Sharma S. Palliation of advanced/recurrent esophageal carcinoma with high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 2002;52:310-5.
10. Homs MY, Eijkenboom WM, Coen VL, Haringsma J, Blankenstein M van, Kuipers EJ, et al. High dose rate brachytherapy for the palliation of malignant dysphagia. Radiother Oncol. 2003;66:327-32.
11. Homs MY, Steyerberg EW, Eijkenboom WM, Tilanus HW, Stalpers W, Bartelsman JF, et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet. 2004;364:1497-504.
12. Homs MYV, Steyerberg EW, Eijkenboom WMH, Tilanus HW, Stalpers LJA, Bartelsman JFWM, et al. Palliatieve behandeling voor slokdarmkanker met passageklachten: gunstiger uitkomsten van eenmalige inwendige brachytherapie dan van plaatsing van een zelfexpanderende stent; multicentrisch, gerandomiseerd onderzoek. Ned Tijdschr Geneeskd. 2005;149:2800-6.
13. Kaneko K, Ito H, Konishi K, Kurahashi T, Ito T, Katagiri A, et al. Definitive chemoradiotherapy for patients with malignant stricture due to 73 or T4 squamous cell carcinoma of the oesophagus. Br J Cancer. 2003;88:18-24.
14. 4 esophageal cancer with or without fistula. Int J Radiat Oncol Biol Phys. 2002;53:134-9.
15. Raemdonck D van, Cutsem E van, Menten J, Ectors N, Coosemans W, Leyn P de, et al. Induction therapy for clinical T4 oesophageal carcinoma; a plea for continued surgical exploration. Eur J Cardiothorac Surg. 1997;11:828-37.
16. Ilson DH. Oesophageal cancer: new developments in systemic therapy. Cancer Treat Rev. 2003;29:525-32.
17. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffie JK, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997;15:261-7.
18. Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer. 1999;80:269-72.
19. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU). With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol. 2002;20:1996-2004.
20. Barr H, Krasner N. Prospective quality-of-life analysis after palliative photoablation for the treatment of malignant dysphagia. Cancer. 1991;68:1660-4.
21. Loizou LA, Rampton D, Atkinson M, Robertson C, Bown SG. A prospective assessment of quality of life after endoscopic intubation and laser therapy for malignant dysphagia. Cancer. 1992;70:386-91.
22. O'Hanlon DM, Harkin M, Karat D, Sergeant T, Hayes N, Griffin SM. Quality-of-life assessment in patients undergoing treatment for oesophageal carcinoma. Br J Surg. 1995;82:1682-5.
23. Blazeby JM, Farndon JR, Donovan J, Alderson D. A prospective longitudinal study examining the quality of life of patients with esophageal carcinoma. Cancer. 2000;88:1781-7.
24. Dallal HJ, Smith GD, Grieve DC, Ghosh S, Penman ID, Palmer KR. A randomized trial of thermal ablative therapy versus expandable metal stents in the palliative treatment of patients with esophageal carcinoma. Gastrointest Endosc. 2001;54:549-57.
25. Homs MY, Essink-Bot ML, Borsboom GJ, Steyerberg EW, Siersema PD. Quality of life after palliative treatment for oesophageal carcinoma - a prospective comparison between stent placement and single dose brachytherapy. Dutch SIREC Study Group. Eur J Cancer. 2004;40:1862-71.
26. Tebbutt NC, Norman A, Cunningham D, Iveson T, Seymour M, Hickish T, et al. A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Ann Oncol. 2002;12:1568-75.
27. Blazeby JM. Measurement of outcome. Surg Oncol. 2001;10:127-33.
28. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-76.
29. Blazeby JM, Alderson D, Winstone K, Steyn R, Hammerlid E, Arraras J, et al. Development of an EORTC questionnaire module to be used in quality of life assessment for patients with oesophageal cancer. The EORTC Quality of Life Study Group. Eur J Cancer. 1996;32A:1912-7.
30. Brooks R. EuroQol: the current state of play. Health Policy. 1996;37:53-72.
31. Blazeby JM, Conroy T, Hammerlid E, Fayers P, Sezer O, Koller M, et al. Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OESI8, to assess quality of life in patients with oesophageal cancer. Eur J Cancer. 2003;39:1384-94.
32. Yu YT, Yang G, Liu Y, Shen BZ. Clinical evaluation of radiotherapy for advanced esophageal cancer after metallic stent placement. World J Gastroenterol. 2004;10:2145-6.